Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALT001 (Wuhan Ailite Biotechnology)
- Development stage
- Unknown
- Lead developer
- Wuhan Ailite Biotechnology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intraarticular
01
Overview
ALT001 is a recombinant humanized type II collagen (rhCol II) being developed for the treatment of osteoarthritis, specifically knee osteoarthritis. Administered via intra-articular injection, the drug is designed to replenish the natural type II collagen that degrades in the articular cartilage during the progression of osteoarthritis. By supplementing the extracellular matrix, ALT001 aims to restore structural integrity, provide lubrication, and reduce mechanical friction within the joint space. This biologic approach is intended to alleviate pain intensity, improve joint motor function, and enhance the quality of life for patients. The development of ALT001 is led by Wuhan Ailite Biotechnology in collaboration with clinical investigators at Union Hospital, Tongji Medical College of Huazhong University of Science and Technology.
- Other names
- Recombinant humanized type II collagenrhCol II
02
Targets
RAB9A (Ras-related protein Rab-9A)
Beyond the preview
Go deeper on ALT001 (Wuhan Ailite Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALT001 (Wuhan Ailite Biotechnology).